アルカリスト（リロナセプト）の世界市場レポート 2025年：疫学、パイプライン分析、市場インサイトと予測

アルカリスト（リロナセプト）の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7％で3億1,170万米ドルに成長します。予測期間の成長は、注射用生物製剤の需要増加、ヘルスケア支出の増加、世界の患者数の増加、炎症性疾患の治療需要の増加、個別化医療の需要増加に起因しています。予測期間における主要動向としては、自己免疫疾患に対する生物学的療法の進歩、製薬企業間の提携、精密医療と標的療法の進歩、技術の進歩、ドラッグデリバリーシステムの革新などが挙げられます。

個別化医療に対する需要の高まりが、今後のアルカリスト（リロナセプト）市場の成長を牽引すると予想されます。個別化医療は、遺伝、環境、ライフスタイルを含む個人の特性に合わせて治療やヘルスケアの決定を行うものです。個別化医療は、治療効果の向上、副作用の軽減、病気の進行や薬剤反応における個人差への対応などの可能性があるため、需要が高まっています。個別化医療が一般的になるにつれて、希少で遺伝的要因に左右される疾患を特定するための認識と診断ツールの向上が進み、その結果、アルカリストが治療できる診断が増加します。例えば、2024年2月、個別化医療連合（PMC）は、FDAが希少疾患患者のために16の新しい個別化治療を承認したと報告しました。さらに、2023年2月、PMCは、2022年にFDAが承認した新たな個別化医薬品は12品目であり、8年連続で個別化医薬品が新薬承認全体の4分の1以上を占めたと報告しています。したがって、個別化医薬品に対する需要の高まりがアルカリスト（リロナセプト）市場の成長を牽引しています。

アルカリスト（リロナセプト）市場の主要動向は、技術統合を強化したアルカリストを開発・商業化し、開発を拡大するために戦略的パートナーシップを採用することです。戦略的パートナーシップにより、企業は互いの強みとリソースを活用し、相互の成功を目指すことができます。例えば、2022年2月、バミューダを拠点とするバイオ製薬会社Kiniksa Pharmaceuticals Ltd.は、中国を拠点とする製薬会社Huadong Medicine Co.Ltd.と提携し、アジア太平洋でアルカリストとマブリリムマブを開発・商業化しました。この契約に基づき、Kiniksaは一時金2,200万米ドルを受領し、開発、薬事承認、販売によるマイルストーン決済で最大6億4,000万米ドルを得る可能性があります。華東医薬は大中華圏、韓国、オーストラリア、その他日本を除く18カ国におけるアルカリストの独占的開発・商業化権を有しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のアルカリスト（リロナセプト）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のアルカリスト（リロナセプト）市場：成長率分析
• 世界のアルカリスト（リロナセプト）市場の実績：規模と成長、2019～2024年
• 世界のアルカリスト（リロナセプト）市場の予測：規模と成長、2024～2029年、2034年
• 世界のアルカリスト（リロナセプト）：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のアルカリスト（リロナセプト）市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 凍結乾燥
• 液体
• 世界のアルカリスト（リロナセプト）市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• クリオピリン関連周期性症候群（CAPS）
• インターロイキン-1受容体拮抗薬欠損症（DIRA）
• その他
• 世界のアルカリスト（リロナセプト）市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のアルカリスト（リロナセプト）市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 成人患者
• 小児患者

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のアルカリスト（リロナセプト）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のアルカリスト（リロナセプト）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• アルカリスト（リロナセプト）市場：競合情勢
• アルカリスト（リロナセプト）市場：企業プロファイル
  • Regeneron Pharmaceuticals Inc.
  • Kiniksa Pharmaceuticals Ltd.

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• アルカリスト（リロナセプト）市場、2029年：新たな機会を提供する国
• アルカリスト（リロナセプト）市場、2029年：新たな機会を提供するセグメント
• アルカリスト（リロナセプト）市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Arcalyst (rilonacept) is a prescription medication classified as an interleukin-1 (IL-1) blocker. It is used to treat inflammatory conditions caused by the overproduction of interleukin-1, a protein that plays a key role in the body's inflammatory response. Rilonacept works by binding to interleukin-1 alpha and beta, preventing their interaction with specific receptors, thus reducing inflammation and alleviating symptoms related to these conditions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary formulations of arcalyst (rilonacept) include lyophilized and liquid forms. The lyophilized version is a freeze-dried formulation designed for reconstitution prior to administration. Arcalyst is indicated for conditions such as cryopyrin-associated periodic syndromes (CAPS), deficiency of interleukin-1 receptor antagonist (DIRA), and other indications. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by both adult and pediatric patients.

The arcalyst (rilonacept) market research report is one of a series of new reports from The Business Research Company that provides arcalyst (rilonacept) market statistics, including arcalyst (rilonacept) industry global market size, regional shares, competitors with a arcalyst (rilonacept) market share, detailed arcalyst (rilonacept) market segments, market trends and opportunities, and any further data you may need to thrive in the arcalyst (rilonacept) industry. This arcalyst (rilonacept) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The arcalyst (rilonacept) market size is expected to see strong growth in the next few years. It will grow to $311.7 million in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to growing demand for injectable biologics, rise in healthcare expenditure, increasing global patient population, rising demand for treatments for inflammatory diseases, rise in demand for personalized medicine. Major trends in the forecast period include advancements in biologic therapies for autoimmune conditions, collaborations between pharmaceutical companies, advances in precision medicine and targeted therapies, technological advancements, innovations in drug delivery systems.

The growing demand for personalized medicines is expected to drive the growth of the arcalyst (rilonacept) market going forward. Personalized medicine tailors treatment and healthcare decisions to an individual's characteristics, including genetics, environment, and lifestyle. The demand for personalized medicine is rising due to its potential to improve treatment effectiveness, reduce adverse effects, and address individual variability in disease progression and drug response. As personalized medicine becomes more common, there is greater awareness and better diagnostic tools to identify rare, genetically driven conditions, which results in an increase in diagnoses that Arcalyst can treat. For instance, in February 2024, the Personalized Medicine Coalition (PMC) reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to just 6 in 2022. Additionally, in February 2023, PMC reported that 12 new personalized medicines were approved by the FDA in 2022, marking the eighth consecutive year where personalized medicines comprised at least a quarter of all new drug approvals. Therefore, the growing demand for personalized medicines is driving the growth of the arcalyst (rilonacept) market.

A key trend in the arcalyst (rilonacept) market is adopting a strategic partnership approach to develop and commercialize Arcalyst with enhanced technology integration and to expand market reach. Strategic partnerships enable companies to leverage each other's strengths and resources to achieve mutual success. For instance, in February 2022, Kiniksa Pharmaceuticals Ltd., a Bermuda-based biopharmaceutical company, partnered with Huadong Medicine Co. Ltd., a China-based pharmaceutical company, to develop and commercialize Arcalyst and mavrilimumab in the Asia-Pacific region. Under this agreement, Kiniksa received an upfront payment of $22 million and could earn up to $640 million through milestone payments based on development, regulatory approvals, and sales. Huadong Medicine holds exclusive rights for the development and commercialization of Arcalyst in Greater China, South Korea, Australia, and 18 other countries, excluding Japan.

In August 2023, Fairmount Funds Management LLC, a South Philadelphia-based investment firm, acquired a stake in Kiniksa Pharmaceuticals for an undisclosed amount. This strategic move is part of Fairmount's broader investment strategy aimed at long-term value generation within the biotechnology sector. Kiniksa Pharmaceuticals is the manufacturer of Arcalyst (rilonacept).

Major players operating in the arcalyst (rilonacept) market are Regeneron Pharmaceuticals Inc., Kiniksa Pharmaceuticals Ltd.

North America was the largest region in the arcalyst (rilonacept) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in arcalyst (rilonacept) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the arcalyst (rilonacept) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The arcalyst (rilonacept) market consists of monoclonal antibodies, anti-inflammatory drugs, rare disease drugs and other related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Arcalyst (rilonacept) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on arcalyst (rilonacept) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for arcalyst (rilonacept) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The arcalyst (rilonacept) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Lyophilized; Liquid
• 2) By Indication: Cryopyrin-Associated Periodic Syndromes (CAPS); Deficiency Of Interleukin-1 Receptor Antagonist (DIRA); Other Indications
• 3) By Distribution Channels: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By End User: Adult Patients; Pediatric Patients
• Companies Mentioned: Regeneron Pharmaceuticals Inc.; Kiniksa Pharmaceuticals Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Arcalyst (Rilonacept) Market Characteristics

3. Arcalyst (Rilonacept) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Arcalyst (Rilonacept) Market Trends And Strategies

5. Arcalyst (Rilonacept) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Arcalyst (Rilonacept) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Arcalyst (Rilonacept) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Arcalyst (Rilonacept) Market Growth Rate Analysis
• 6.4. Global Arcalyst (Rilonacept) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Arcalyst (Rilonacept) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Arcalyst (Rilonacept) Total Addressable Market (TAM)

7. Global Arcalyst (Rilonacept) Market Pricing Analysis & Forecasts

8. Arcalyst (Rilonacept) Market Segmentation

• 8.1. Global Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lyophilized
• Liquid
• 8.2. Global Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cryopyrin-Associated Periodic Syndromes (CAPS)
• Deficiency Of Interleukin-1 Receptor Antagonist (DIRA)
• Other Indications
• 8.3. Global Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 8.4. Global Arcalyst (Rilonacept) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult Patients
• Pediatric Patients

9. Global Arcalyst (Rilonacept) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Arcalyst (Rilonacept) Market Regional And Country Analysis

• 10.1. Global Arcalyst (Rilonacept) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Arcalyst (Rilonacept) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Arcalyst (Rilonacept) Market

• 11.1. Asia-Pacific Arcalyst (Rilonacept) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Arcalyst (Rilonacept) Market

• 12.1. China Arcalyst (Rilonacept) Market Overview
• 12.2. China Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Arcalyst (Rilonacept) Market

• 13.1. India Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Arcalyst (Rilonacept) Market

• 14.1. Japan Arcalyst (Rilonacept) Market Overview
• 14.2. Japan Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Arcalyst (Rilonacept) Market

• 15.1. Australia Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Arcalyst (Rilonacept) Market

• 16.1. South Korea Arcalyst (Rilonacept) Market Overview
• 16.2. South Korea Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Arcalyst (Rilonacept) Market

• 17.1. Western Europe Arcalyst (Rilonacept) Market Overview
• 17.2. Western Europe Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Arcalyst (Rilonacept) Market

• 18.1. UK Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Arcalyst (Rilonacept) Market

• 19.1. Germany Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Arcalyst (Rilonacept) Market

• 20.1. France Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Arcalyst (Rilonacept) Market

• 21.1. Eastern Europe Arcalyst (Rilonacept) Market Overview
• 21.2. Eastern Europe Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Arcalyst (Rilonacept) Market

• 22.1. North America Arcalyst (Rilonacept) Market Overview
• 22.2. North America Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Arcalyst (Rilonacept) Market

• 23.1. USA Arcalyst (Rilonacept) Market Overview
• 23.2. USA Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Arcalyst (Rilonacept) Market

• 24.1. Canada Arcalyst (Rilonacept) Market Overview
• 24.2. Canada Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Arcalyst (Rilonacept) Market

• 25.1. South America Arcalyst (Rilonacept) Market Overview
• 25.2. South America Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Arcalyst (Rilonacept) Market

• 26.1. Middle East Arcalyst (Rilonacept) Market Overview
• 26.2. Middle East Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Arcalyst (Rilonacept) Market

• 27.1. Africa Arcalyst (Rilonacept) Market Overview
• 27.2. Africa Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Arcalyst (Rilonacept) Market Competitive Landscape And Company Profiles

• 28.1. Arcalyst (Rilonacept) Market Competitive Landscape
• 28.2. Arcalyst (Rilonacept) Market Company Profiles
  • 28.2.1. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. Kiniksa Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis

29. Global Arcalyst (Rilonacept) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Arcalyst (Rilonacept) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Arcalyst (Rilonacept) Market

32. Recent Developments In The Arcalyst (Rilonacept) Market

33. Arcalyst (Rilonacept) Market High Potential Countries, Segments and Strategies

• 33.1 Arcalyst (Rilonacept) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Arcalyst (Rilonacept) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Arcalyst (Rilonacept) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer